Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $240
Revolution Medicines
Revolution Medicines RVMD | 0.00 |
Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:
RVMD) with a Buy and raises the price target from $235 to $240.
